Genmab A/S (GNMSF)
- Previous Close
289.67 - Open
280.41 - Bid --
- Ask --
- Day's Range
279.36 - 294.54 - 52 Week Range
262.00 - 426.50 - Volume
343 - Avg. Volume
1,016 - Market Cap (intraday)
18.83B - Beta (5Y Monthly) 0.78
- PE Ratio (TTM)
30.76 - EPS (TTM)
9.44 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and GEN3017 for treating hematological malignancies. In addition, the company develops Inclacumab, which is in Phase 3 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. It operates various active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, and Novo Nordisk A/S. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.
www.genmab.comRecent News: GNMSF
Performance Overview: GNMSF
Trailing total returns as of 4/24/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: GNMSF
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: GNMSF
Valuation Measures
Market Cap
18.59B
Enterprise Value
14.69B
Trailing P/E
30.79
Forward P/E
26.11
PEG Ratio (5yr expected)
1.26
Price/Sales (ttm)
8.13
Price/Book (mrq)
4.17
Enterprise Value/Revenue
0.89
Enterprise Value/EBITDA
2.46
Financial Highlights
Profitability and Income Statement
Profit Margin
26.42%
Return on Assets (ttm)
10.17%
Return on Equity (ttm)
14.78%
Revenue (ttm)
16.47B
Net Income Avi to Common (ttm)
4.35B
Diluted EPS (ttm)
9.44
Balance Sheet and Cash Flow
Total Cash (mrq)
28.14B
Total Debt/Equity (mrq)
2.44%
Levered Free Cash Flow (ttm)
5.29B
Research Analysis: GNMSF
Company Insights: GNMSF
GNMSF does not have Company Insights